18F-FDG-PET/CT代谢肿瘤参数与循环肿瘤DNA评估儿童及青少年尤文肉瘤治疗反应
该前瞻性研究对20例组织学确诊的尤文肉瘤儿童及青少年进行多次18F-FDG-PET/CT和ctDNA检测,分析代谢参数与ctDNA水平的相关性及治疗反应一致性。结果显示SUVmax、SUVmean、wb-MTV和wb-TLG与ctDNA水平显著相关(均p<0.0001),第五个诱导化疗后代谢反应与生化反应一致率为90%(Cohen κ=0.62;p<0.05)。
要点
- 18F-FDG-PET/CT代谢参数与ctDNA水平显著相关(均p<0.0001)。
- 第五个诱导化疗后代谢反应与生化反应一致率90%(κ=0.62;p<0.05)。
- 第二个化疗后ctDNA不可测者中94%(16/17)在第五个化疗后达完全生化及代谢反应。
核心结论
- 18F-FDG-PET/CT与ctDNA定量联合是评估尤文肉瘤患儿多模式化疗治疗反应和检测肿瘤复发的有前景的无创工具。
研究设计与样本
- 前瞻性研究纳入20例组织学确诊的尤文肉瘤儿童及青少年,在初诊时及第2、第5个诱导化疗后行18F-FDG-PET/CT(EWING2008方案,NCT00987636),共87次扫描。
- 对所有263个视野内18F-FDG阳性可疑肿瘤病灶进行定量分析,计算SUVmax、SUVmean、wb-MTV和wb-TLG。
- 采用数字微滴PCR(ddPCR)定量患者血浆肿瘤特异性ctDNA,分析ctDNA水平与PET参数的相关性,并比较代谢反应与生化反应。
主要发现
- SUVmax、SUVmean、wb-MTV和wb-TLG值与ctDNA水平均显著相关(均p<0.0001)。
- 以组织学为金标准,所有尤文肉瘤患者在治疗开始前ctDNA样本阳性且18F-FDG-PET/CT检查阳性,无假阴性结果。
- 第五个诱导化疗后代谢反应与生化反应一致率为90%,具有统计学显著性(Cohen κ=0.62;p<0.05)。
- 第二个诱导化疗后ctDNA不可测与第五个诱导化疗后完全生化及代谢反应相关,16/17例(94%)达到。
- 中位随访36个月(范围8-104个月)期间4例肿瘤复发,均伴随血浆ctDNA水平升高和18F-FDG-PET/CT阳性,无假阴性结果。
关键数值与推荐
- 代谢反应与生化反应一致率90%(Cohen κ=0.62;p<0.05),评估时间为第五个诱导化疗后。
- 第二个诱导化疗后ctDNA不可测者中94%(16/17)在第五个诱导化疗后达完全生化及代谢反应。
- 第五个诱导化疗后完全生化及代谢反应对随访期疾病缓解的阳性预测值为88%。
临床怎么用
- 对于接受多模式化疗的尤文肉瘤儿童及青少年,可联合18F-FDG-PET/CT代谢参数与ctDNA定量评估治疗反应。
- 第二个诱导化疗后ctDNA不可测可能提示后续完全生化及代谢反应,可辅助治疗决策。
- 随访中18F-FDG-PET/CT阳性伴ctDNA升高需警惕肿瘤复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to perform a prospective integrated analysis of 18F-fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) and circulating tumor DNA (ctDNA) to assess responses to multimodal chemotherapy in children and adolescents suffering from Ewing sarcoma (EwS). METHODS: A total of 20 patients with histologically confirmed EwS underwent multiple 18F-FDG-PET/CT, performed at the time of each patient's initial diagnosis and after the second and fifth induction chemotherapy block (EWING2008 treatment protocol, NCT00987636). Additional PET examinations were performed as clinically indicated in some patients, e.g., in patients suspected of having progressive or relapsing disease. All 263 18F-FDG-positive lesions in the field of view suggestive of tumor tissue were assessed quantitatively to calculate PET-derived parameters, including whole-body metabolic tumor volume (wb-MTV) and whole-body total lesion glycolysis (wb-TLG), as well as the following data: standardized uptake value (SUV)max and SUVmean. Tumor-specific ctDNA in patient plasma samples was quantified using digital droplet PCR (ddPCR), and the correlations between ctDNA levels and PET-derived parameters were analyzed. Metabolic responses to multimodal chemotherapy as assessed with PET-parameters were compared to biochemical responses as assessed with changes in ctDNA levels. RESULTS: Twenty patients underwent a total of 87 18F-FDG-PET/CT scans, which detected 263 FDG-positive tumor lesions. Significant correlations between SUVmax, SUVmean, wb-MTV and wb-TLG values, and ctDNA levels were observed (all p < 0.0001). All patients suffering from EwS, with histology serving as gold standard, also presented with a positive corresponding ctDNA sample and a positive 18F-FDG-PET/CT examination before initiation of therapy. There were no false-negative results. Evaluation of treatment response after the fifth block of induction chemotherapy showed that the agreement between the metabolic response and biochemical response was 90%, which was statistically significant (Cohen κ = 0.62; p < 0.05). Non-detectable ctDNA after the second block of induction chemotherapy was associated with complete biochemical and metabolic responses after the fifth block of induction chemotherapy in 16/17 patients (94%). During a median follow-up period of 36 months (range: 8-104 months), four patients had tumor relapses, which, in all cases, were accompanied by an increase in plasma ctDNA levels and a positive 18F-FDG-PET/CT. No false-negative results were observed in the study cohort. Complete biochemical and metabolic responses after the fifth block of induction chemotherapy had a high positive predictive value for disease remission during the follow-up period; specifically, the positive predictive value was 88%. CONCLUSION: The combination of 18F-FDG-PET/CT and ctDNA quantification is a very promising noninvasive tool for assessing treatment responses and detecting tumor relapses in children and young adolescents suffering from EwS who are undergoing multimodal chemotherapy.
引用
- Schmidkonz C, Krumbholz M, Atzinger A, et al. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA. Eur J Nucl Med Mol Imaging. 2019. PMID: 31853559. doi:10.1007/s00259-019-04649-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。